Komori
Cuorips (4894) · RiskMitigated

Risks of intellectual-property infringement, failure to obtain rights and license terms

First written in FY2023. 2 of 3 entries say "Mitigated", first in FY2025. Latest entry: FY2026.

3entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023MitigatedFY2025 – FY20262023: 120232024: 020242025: 120252026: 12026
Same theme, other companies

The whole theme swung hardest in 2020: 4 of 43 companies on the "Worse" side.

14 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 108 companies compared. The sentences above are computed from all 108.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「For technologies, know-how and other assets acquired through research and development, the Group seeks to secure intellectual property rights, including patents in Japan and overseas, based on advice from patent attorneys and others.」

    In addition to Japan and Europe, the company obtained U.S. patents related to CLiC-1 and disclosed a system for investigating third-party infringement, further specifying its intellectual-property protections.
  2. FY2025MitigatedAnnual report

    「For technologies, know-how and other assets acquired through research and development, the Group seeks to secure intellectual property rights, including patents in Japan and overseas, based on advice from patent attorneys and others.」

    The company disclosed patents obtained in Japan and Europe and systems for securing rights and investigating infringement in Japan and overseas, making some intellectual-property risk responses more concrete. Risks of third-party infringement, rejection of registration and inability to obtain licenses remain.
  3. FY2023First statedAnnual report

    「If intellectual property filed by us in Japan and other countries is not registered because of a final rejection, or if a competitor files first and obtains the rights, we may be unable to obtain legal protection for or use the intellectual property, which could affect our business activities.」

    The company also cites infringement by third parties, infringement of third-party rights by the company, disputes over compensation for inventions, and inability to obtain licenses or increased license costs.
Moved together

"Obtained manufacturing and marketing approval for human iPS cell-derived cardiac muscle cell sheets and their commercialization" moved the same way as this thread, in the same document, in 2 of its 3 moves.

222222★123456
  1. ★This thread
  2. 1Obtained manufacturing and marketing approval for human iPS cell-derived cardiac muscle cell sheets and their commercialization2×
  3. 2Approval obtained for a myocardial cell sheet in the United States and Europe, with expansion of sales regions2×
  4. 3Establishment of Manufacturing and Marketing Licensing, Sales and Distribution, and Information-Provision Systems2×
  5. 4Expanding the one-stop CDMO business using CLiC-12×
  6. 5Expansion of the Cell Culture Processing Facility2×
  7. 6Securing intellectual property rights and avoiding infringement of third-party rights2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Cuorips yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risks of intellectual-property infringement, failure to obtain rights and license terms | Cuorips Inc. (4894) | Komori